Skip to main content

Table 1 Demographic and clinical characteristics evaluated during the 12-month baseline period

From: Healthcare resource utilization and costs associated with inflammatory bowel disease among patients with chronic inflammatory diseases: a retrospective cohort study

 

Non-CID cohort (not diagnosed with RA, PsA, PsO or AS)

All patients: RA, PsO, PsA, or AS cohort

Patients with RA

Patients with PsO and PsA

Patients with PsO but without PsA

Patients with AS

Patients with AS, PsO or PsA

(N = 1,008,436)

(N = 537,450)

(N = 206,260)

(N = 21,250)

(N = 124,950)

(N = 16,029)

(N = 183,318)

Agea, mean ± SD

46.3 ± 16.3

54.0 ± 14.7

57.5 ± 13.7

51.4 ± 12.2

51.1 ± 15.1

49.4 ± 13.8

51.3 ± 14.4

Female, %

55.1%

63.1%

75.8%

52.8%

51.5%

43.8%

51.3%

Payment type, %

 Commercial

88.9%

79.3%

73.6%

89.0%

83.6%

88.3%

84.9%

 Medicare

11.1%

20.7%

26.4%

11.0%

16.4%

11.7%

15.1%

Region of residencea, %

 South

39.0%

37.5%

39.1%

40.2%

36.2%

36.3%

36.8%

 North Central

21.9%

22.4%

23.0%

20.2%

22.4%

19.1%

21.7%

 West

18.9%

16.8%

16.5%

17.6%

16.7%

24.9%

17.4%

 North East

18.9%

22.4%

20.5%

21.0%

24.0%

18.9%

23.2%

 Unknown

1.4%

0.8%

0.8%

1.1%

0.8%

0.8%

0.9%

Year of index date, %

 2011

30.9%

24.8%

28.2%

23.4%

26.0%

25.7%

25.9%

 2012

19.2%

17.8%

17.5%

14.4%

17.8%

16.6%

17.4%

 2013

16.8%

15.8%

15.1%

14.6%

15.6%

14.8%

15.4%

 2014

13.0%

13.4%

12.3%

13.4%

13.5%

12.5%

13.3%

 2015

16.9%

16.0%

14.5%

19.1%

15.8%

16.9%

16.2%

 2016

3.3%

12.2%

12.4%

15.1%

11.3%

13.5%

11.9%

Quan-Charlson Comorbidity Indexb, mean ± SD

0.5 ± 1.1

1.2 ± 1.5

1.9 ± 1.4

0.9 ± 1.3

0.7 ± 1.2

0.9 ± 1.3

0.7 ± 1.3

Extra-articular manifestationsb,c, %

12.4%

43.5%

27.3%

100.0%

100.0%

32.5%

84.8%

Gastro-related conditionsb,d, %

13.6%

18.8%

22.1%

19.5%

15.3%

22.5%

16.7%

Drug useb, %

 NSAIDS

17.0%

33.3%

43.7%

42.5%

20.5%

51.5%

28.3%

 Corticosteroids

19.5%

45.3%

62.3%

49.3%

33.4%

47.7%

38.2%

 Biologics

0.1%

21.0%

31.9%

54.3%

16.4%

44.9%

27.0%

 PDE4 inhibitors

0.0%

0.4%

0.1%

3.2%

0.9%

0.1%

1.2%

 Opioids

24.0%

38.8%

50.0%

42.3%

27.6%

50.0%

33.1%

 DMARDs

1.5%

37.6%

67.1%

56.4%

17.4%

39.4%

28.8%

  1. CID Chronic inflammatory disease, SD Standard deviation, HRU Healthcare resource utilization, RA Rheumatoid arthritis, PsA Psoriatic arthritis, PsO Psoriasis, AS Ankylosing spondylitis, NSAIDs Non-steroidal anti-inflammatory drugs, DMARDS Disease modifying anti-rheumatic drugs
  2. aMeasured at the index date.
  3. bMeasured during the 12-month baseline period.
  4. cExtra-articular manifestations include cutaneous, ocular, cardiovascular, urogenital, pulmonary, and other manifestations such as enthesopathies, parapsoriasis, pityriasis, and other psoriasis and similar disorders.
  5. dGastro-related conditions include diarrhea, weight loss, blood in stool, abdominal pain, gastrointestinal hemorrhage, ischemic colitis, dyspepsia, and gastroenteritis.